BTK and hematologic disorder: Since the BTK structure and function were well defined in 1993 by Vetrie et al. [8], BTK inhibitors (BTKIs) have been studied for the treatment of different haematological disorders (particularly of B-cell malignancies) [9] and of many autoimmune diseases; consequently, many investigations by industry and academia have been performed.